Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Palisade Bio, Inc. (NASDAQ:PALI) have received an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $20.50.

Several brokerages have recently weighed in on PALI. Clear Str upgraded Palisade Bio to a “strong-buy” rating in a research note on Monday, December 29th. Piper Sandler began coverage on Palisade Bio in a report on Monday, December 29th. They issued an “overweight” rating and a $25.00 price target for the company. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a report on Saturday. Citigroup reaffirmed a “buy” rating on shares of Palisade Bio in a research report on Tuesday, November 11th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Palisade Bio in a research note on Wednesday, October 8th.

Palisade Bio Stock Down 16.0%

PALI opened at $2.10 on Thursday. The firm’s 50 day moving average is $2.02 and its 200-day moving average is $1.34. Palisade Bio has a 52-week low of $0.53 and a 52-week high of $2.64. The firm has a market capitalization of $312.90 million, a P/E ratio of -0.99 and a beta of 1.43.

Palisade Bio (NASDAQ:PALI) last announced its earnings results on Monday, November 10th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.06). Equities analysts expect that Palisade Bio will post -12.43 earnings per share for the current fiscal year.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.